{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:12:18Z","timestamp":1721520738454},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,20]]},"DOI":"10.7759\/cureus.65007","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T21:59:10Z","timestamp":1721512750000},"source":"Crossref","is-referenced-by-count":0,"title":["Mechanical Aortic Valve Thrombosis During Anticoagulation Using Oral Rivaroxaban: A Case Report"],"prefix":"10.7759","author":[{"given":"Ryoji","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiju","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryumon","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunobu","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026793","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis","volume":"135","author":"Siontis KC","year":"2017","unstructured":"Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis. Circulation. 2017, 135:714-6. 10.1161\/CIRCULATIONAHA.116.026793","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es HP","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros E Silva PG, et al.. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020, 383:2117-26. 10.1056\/NEJMoa2029603","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000932","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"143","author":"Otto CM","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al.. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021, 143:e35-71. 10.1161\/CIR.0000000000000932","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"43","author":"Vahanian A","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al.. 2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022, 43:561-632. 10.1093\/eurheartj\/ehab395","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-13-2-73","article-title":"Mechanical valve thrombosis on rivaroxaban: are novel anticoagulants really an option?","volume":"13","author":"Kumar V","year":"2017","unstructured":"Kumar V, Kelly S, Raizada A, Yee J, Anuwatworn A, Stys A, Stys M. Mechanical valve thrombosis on rivaroxaban: are novel anticoagulants really an option?. Methodist Debakey Cardiovasc J. 2017, 13:73-5. 10.14797\/mdcj-13-2-73","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000501361","article-title":"Mechanical prosthetic heart valve thrombosis in a patient receiving rivaroxaban","volume":"143","author":"Carvalho Silva DM","year":"2019","unstructured":"Carvalho Silva DM, Braga A, de Jesus I, Neves J. Mechanical prosthetic heart valve thrombosis in a patient receiving rivaroxaban. Cardiology. 2019, 143:116-20. 10.1159\/000501361","journal-title":"Cardiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study","volume":"16","author":"Dur\u00e3es AR","year":"2016","unstructured":"Dur\u00e3es AR, de Souza Roriz P, de Almeida Nunes B, Albuquerque FP, de Bulh\u00f5es FV, de Souza Fernandes AM, Aras R. Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D. 2016, 16:149-54. 10.1007\/s40268-016-0124-1","journal-title":"Drugs R D"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037955","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight: insights from the ARISTOTLE trial","volume":"139","author":"Hohnloser SH","year":"2019","unstructured":"Hohnloser SH, Fudim M, Alexander JH, et al.. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight: insights from the ARISTOTLE trial. Circulation. 2019, 139:2292-300. 10.1161\/CIRCULATIONAHA.118.037955","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli AP","year":"2017","unstructured":"Carnicelli AP, De Caterina R, Halperin JL, et al.. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017, 135:1273-5. 10.1161\/CIRCULATIONAHA.116.026714","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-314767","article-title":"Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves","volume":"105","author":"Malik AH","year":"2019","unstructured":"Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart. 2019, 105:1432-6. 10.1136\/heartjnl-2019-314767","journal-title":"Heart"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom JW","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al.. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013, 369:1206-14. 10.1056\/NEJMoa1300615","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.12.005","article-title":"Rivaroxaban in patients with mechanical heart valves: a pilot study","volume":"186","author":"Roost E","year":"2020","unstructured":"Roost E, Weber A, Alberio L, et al.. Rivaroxaban in patients with mechanical heart valves: a pilot study. Thromb Res. 2020, 186:1-6. 10.1016\/j.thromres.2019.12.005","journal-title":"Thromb Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.06.015","article-title":"Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis","volume":"122","author":"Dur\u00e3es AR","year":"2018","unstructured":"Dur\u00e3es AR, Bitar YS, Lima ML, Santos CC, Schonhofen IS, Filho JA, Roever L. Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis. Am J Cardiol. 2018, 122:1047-50. 10.1016\/j.amjcard.2018.06.015","journal-title":"Am J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00449-3","article-title":"Rivaroxaban versus warfarin in patients with mechanical heart valves: open-label, proof-of-concept trial-the Riwa study","volume":"21","author":"Duraes AR","year":"2021","unstructured":"Duraes AR, de Souza Lima Bitar Y, Schonhofen IS, et al.. Rivaroxaban versus warfarin in patients with mechanical heart valves: open-label, proof-of-concept trial-the Riwa study. Am J Cardiovasc Drugs. 2021, 21:363-71. 10.1007\/s40256-020-00449-3","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.702780","article-title":"Antithrombotic treatment after surgical and transcatheter heart valve repair and replacement","volume":"8","author":"Verstraete A","year":"2021","unstructured":"Verstraete A, Herregods MC, Verbrugghe P, et al.. Antithrombotic treatment after surgical and transcatheter heart valve repair and replacement. Front Cardiovasc Med. 2021, 8:702780. 10.3389\/fcvm.2021.702780","journal-title":"Front Cardiovasc Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.535","article-title":"Anticoagulation and antiplatelet strategies after On-X mechanical aortic valve replacement","volume":"71","author":"Puskas JD","year":"2018","unstructured":"Puskas JD, Gerdisch M, Nichols D, et al.. Anticoagulation and antiplatelet strategies after On-X mechanical aortic valve replacement. J Am Coll Cardiol. 2018, 71:2717-26. 10.1016\/j.jacc.2018.03.535","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.06.014","article-title":"Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X aortic heart valve","volume":"227","author":"Jawitz OK","year":"2020","unstructured":"Jawitz OK, Wang TY, Lopes RD, et al.. Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X aortic heart valve. Am Heart J. 2020, 227:91-9. 10.1016\/j.ahj.2020.06.014","journal-title":"Am Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273394-mechanical-aortic-valve-thrombosis-during-anticoagulation-using-oral-rivaroxaban-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T21:59:13Z","timestamp":1721512753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273394-mechanical-aortic-valve-thrombosis-during-anticoagulation-using-oral-rivaroxaban-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.65007","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,20]]}}}